NCT06608199RecruitingPhase 3
A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered with Hexavalent Vaccine At 2, 4 and 12-15 Months of Age to Healthy Infants in Indonesia
Beijing Minhai Biotechnology Co., Ltd3 sites in 1 country500 target enrollmentStarted: November 1, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 500
- Locations
- 3
- Primary Endpoint
- Immugenocity
Study Overview
Brief Summary
The goal of this clinical trial is to evaluate the immunogenicity and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine (PCV13) when co-administered with Hexavalent Vaccines at 2,4, and 12-15 months of age, to healthy infants in Indonesia. This study aims to demonstrate the non-inferiority of the serotype-specific immune responses elicited by the novel PCV13-DT/TT (Pneuminvac) as compared to PCV13(Prevenar 13) one month after the booster dose, and evaluate the safety of PCV13 co-administrated with Hexavalent Vaccine(Hexaxim).
Detailed Description
A total of approximately 500 infants 6-8 weeks of age (WOA) will be enrolled and randomized in 1:1 ratio into the study group and control group, with 250 participants in each group.The study group will receive study PCV13 vaccine and control group will receive Prevenar13® vaccine at 2, 4 and 12-15 months of age (MOA, as early as 6 weeks of age as per WHO recommendations for administration of PCV to infants). Hexavalent vaccine will be injected at 2, 3 and 4 months of age.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 6 Weeks to 8 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy infants based on medical history and clinical assessment.
- •Infants age of 6-8 weeks at enrolment. Infants will be eligible since the day they reach 6 weeks of age and until 8 weeks of age included.
- •*Body weight at enrollment ≥3.0 kg (If the subject does not meet the criteria, the visit may be rescheduled when the criteria is met.).
- •*On the day of vaccination and within 3 days prior to 1st dose of vaccination, axillary temperatures <37.5°C/99.1°F (If the subject does not meet the criteria, the visit may be rescheduled when the criteria is met.).
- •Infant's parent(s) or legal guardian must be able and willing to provide voluntary written/thumb-printed informed consent for the infant to participate in the study.
- •Infant's parent(s) or legal guardian must be willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
- •The infant's mother must provide related medical certificate(s) for the negative results for HIV, HBV and syphilis infection within 1 year prior to screening.
- •Infant's parent(s) or legal guardian must have a readily identifiable place of residence in the study area, be available for the duration of trial participation, and have a means of telephone contact.
- •Note: For items with an asterisk (*), If the subject does not meet the criteria, the visit may be rescheduled when the criteria is met.
Exclusion Criteria
- •Use of any investigational product other than that used in the study prior to randomization or planned use of such a product during the period of study participation.
- •History of S. pneumoniae infection as confirmed by laboratory testing if available.
- •The infant who are children in care, preterm and low-birth-weight (Preterm infants have a gestational age below 37 weeks at birth and low-birth-weight infants have a birth weight below 2.5 kg).
- •History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the investigational vaccine. And/or all components of the hexavalent vaccine.
- •History of anaphylactic shock.
- •Any abnormal vital sign as judged by the investigator.
- •*Participant experiences acute diseases or acute exacerbation of chronic diseases or uses antipyretic, analgesic and anti-allergic drugs (such as paracetamol, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days before vaccination.
- •*History of administration of attenuated vaccines within 14 days (<14 days) and inactivated vaccines within 7 days (<7 days) prior to the 1st dose of investigational vaccine (If the participant[s] does not meet the criteria, the visit may be rescheduled when the criteria are met).
- •Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Neisseria meningitidis and/or Streptococcus pneumoniae with the exception of vaccines where the first dose can be given before 2 months of life according to the national recommendations.
- •History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease, Neisseria meningitidis.
- •Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥10 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids within indicated dosage are permitted.
- •*Administration of immunoglobulins and/or any blood products or anticipation of such administration within 28 days before vaccination and during the study period.
- •History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding (e.g., thalassemia, coagulation factors deficiency, severe anemia at birth).
- •History of suspected primary immunodeficiency.
- •History of meningitis, seizures or any neurological disorder.
- •A family history of congenital or hereditary immunodeficiency.
- •The infant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the CRO, the investigator, study site personnel.
- •Any medical or social condition that in the opinion of the investigator may compromise the well-being of the study participant, interfere with the study objectives, pose a risk to the study participant, or prevent the study participant from completing the study follow-up.
- •Note: For items with an asterisk (*), if the participant meets these exclusion criteria, the visit may be rescheduled for a time when these criteria are not met.
Arms & Interventions
PCV13-DT/TT(Pneuminvac)
Experimental
250 infants will be administered with Minhai's PCV13-DT/TT(Pneuminvac)
Intervention: pneumococcal disease prevention (Biological)
PCV13(Prenenar13)
Active Comparator
250 infants will be administered with Prenenar13
Intervention: pneumococcal disease prevention (Biological)
Outcomes
Primary Outcomes
Immugenocity
Time Frame: 1. Percentage of participants with serotype-specific IgG concentrations ≥ 0.35 μg/mL, measured 30 days after the booster dose of the investigational vaccine. 2. GMC ratio of serotype-specific IgG responses 30 days after the booster dose of the investigat
1. To evaluate the serotype-specific IgG responses 30 days after booster dose of the investigational vaccine.
Secondary Outcomes
- Safety(3. Incidence, severity, and causality of SAEs from 1st dose to 6 months after booster dose of the investigational vaccine.)
- Immugenocity(1. Percentage of participants with serotype-specific IgG concentrations ≥ 0.35 μg/mL, measured 30 days after 2nd dose of the investigational vaccine. 2. GMC of serotype-specific IgG responses 30 days after 2nd dose of the investigational vaccine. 3. Pe)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13Pneumococcal Disease, InvasiveNCT05934890Walvax Biotechnology Co., Ltd.630
Completed
Phase 3
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsVaccines, PneumococcalNCT00366548Wyeth is now a wholly owned subsidiary of Pfizer500
Completed
Phase 3
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsVaccines, PneumococcalNCT00366678Wyeth is now a wholly owned subsidiary of Pfizer613
Completed
Phase 3
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsVaccines, PneumococcalNCT00474539Wyeth is now a wholly owned subsidiary of Pfizer449
Completed
Phase 3
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.Vaccines, PneumococcalNCT00368966Wyeth is now a wholly owned subsidiary of Pfizer619